Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331111 | 0.84 | AXL (0.54) | MEN1KMT2AKDM4ECDK2NPC1 | |
| SCHEMBL13024368 | 0.84 | TNIK (0.47) | KMT2AALDH1A1KDM4ETRPV1CDK1 | |
| SCHEMBL22353107 | 0.82 | ALDH1A1 (0.44) | MEN1KMT2AUSP2ALDH1A1CDK1 | |
| SCHEMBL5352040 | 0.82 | SMN1; SMN2 (0.56) | MEN1KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL14624000 | 0.81 | RAB9A (0.55) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4744555 | 0.80 | KIF11 (0.44) | RAB9A | |
| SCHEMBL9051628 | 0.79 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL9053060 | 0.78 | TP53 (0.42) | KMT2AALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13024370 | 0.78 | MAPT (0.61) | MEN1KMT2AUSP2ALDH1A1KDM4E | |
| SCHEMBL28850934 | 0.78 | LOXL2 (0.44) | MEN1KMT2AUSP2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20220388963-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220106274-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11034657-B2 | Liver X receptor (LXR) modulators | ELLORA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3041835-B1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2013130892-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | ANAYADERM, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130892-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | ANAYADERM, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106274-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | MEN1 4804/4885KMT2A 2885/4885USP2 2912/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | MEN1 4504/4885KMT2A 3587/4885USP2 2666/4885 |
| US-11034657-B2 | Liver X receptor (LXR) modulators | NR1H2, NR1H3, NR1H4 | MEN1 4804/4885KMT2A 2885/4885USP2 2912/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MEN1 2422/4885KMT2A 1346/4885USP2 3639/4885 |
| US-20220388963-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | MEN1 4804/4885KMT2A 2885/4885USP2 2912/4885 |
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | MEN1 3666/4885KMT2A 2663/4885USP2 4131/4885 |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | MEN1 4797/4885KMT2A 2875/4885USP2 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.